NewslettersProstate Cell NewsOncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate CancerBy lbeveridge - October 27, 2023051ONCT-534 interacts with both the N-terminal domain and the ligand-binding domain of the androgen receptor, inhibiting cell growth and inducing androgen receptor degradation.[Oncternal Therapeutics, Inc.]Press Release